Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: Results from a multicenter study

Blood

Volumn 119, Issue 16, 2012, Pages 3698-3704

  Czuczman, Myron S ^a   Fayad, Luis ^b   Delwail, Vincent ^c   Cartron, Guillaume ^d   Jacobsen, Eric ^e   Kuliczkowski, Kazimierz ^f   Link, Brian K ^g   Pinter Brown, Lauren ^h   Radford, John ⁱ   Hellmann, Andrzej ^j   Gallop Evans, Eve ^k   DiRienzo, Christine G ^l   Goldstein, Nancy ^l   Gupta, Ira ^l   Jewell, Roxanne C ^l   Lin, Thomas S ^l   Lisby, Steen ^m   Schultz, Martin ^m   Russell, Charlotte A ^m   Hagenbeek, Anton ⁿ  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k VELINDRE CANCER CENTRE   (United Kingdom)

^l GLAXOSMITHKLINE   (United States)

^m Genmab   (Denmark)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; OFATUMUMAB; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; COUGHING; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SEPSIS; STEADY STATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; URTICARIA;

EID: 84860344201     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-378323     Document Type: Article

References (39)

1. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol. 2000;18(17):3135-3143.
2. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-4423. (Pubitemid 38745964)
3. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088-1095. (Pubitemid 46202263)
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
5. Kahl BS, Bartlett NL, Leonard JP, et al. Benda-mustine is effective therapy in patients with ritux-imab-refractory, indolent B-cell non-Hodgkin lym-phoma: results from a Multicenter Study. Cancer. 2010;116(1):106-114.
6. Lewington V. Development of 131I-tositumomab. Semin Oncol. 2005;32(1 Suppl 1):S50-S56.
7. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositu-momab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712-719. (Pubitemid 46224170)
8. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lym-phomas. J Clin Oncol. 2000;18(6):1316-1323. (Pubitemid 30159851)
9. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(15): 3262-3269. (Pubitemid 34831524)
10. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204-210.
11. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43(11):1507-1529. (Pubitemid 35285877)
12. Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am Soc Hematol Educ Program. 2005;2005: 335-339.
13. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202-1208.
14. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101-106. (Pubitemid 32061248)
15. Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lym-phoma. J Clin Oncol. 2002;20(20):4261-4267. (Pubitemid 35191030)
16. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007; 2007:233-242.
17. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
18. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. (Pubitemid 43939148)
19. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 mono-clonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908. (Pubitemid 30412866)
20. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007; 67(21):10556-10563. (Pubitemid 350070832)
21. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24(3):263-271. (Pubitemid 32479718)
22. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101(3): 949-954. (Pubitemid 36139365)
23. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12(13): 4027-4035. (Pubitemid 44078090)
24. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-1570. (Pubitemid 351413941)
25. Daydé D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765-3772.
26. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181(1):822-832.
27. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatu-mumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749-758.
28. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800. (Pubitemid 39202289)
29. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495.
30. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Vol 3. Lyon, France: International Agency for Research on Cancer; 2001.
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
32. Kennedy AD, Beum PV, Solga MD, et al. Ritux-imab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280-3288. (Pubitemid 38263720)
33. Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009; 113(16):3809-3812.
34. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JS, Czuczman MS. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma [abstract]. J Clin Oncol. 2010;28(suppl):8095.
35. Czuczman MS, Viardot A, Hess G, et al. Ofatumumab combined with CHOP in previously un-treated patients with follicular lymphoma (FL) [abstract]. J Clin Oncol. 2010;28(suppl):8042.
36. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
37. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lym-phoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
38. Wierda W, O'Brien S, Wen S, et al. Chemoimmu-notherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18): 4070-4078. (Pubitemid 46211312)
39. Grillo-López AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol. 2000;11(4):399-408. (Pubitemid 30333541)